Precede Biosciences
Precede Biosciences is a precision diagnostics and data company focused on enabling the next generation of precision medicines, with an initial emphasis on cancer. The company develops a blood-based platform that integrates a single, automated assay with machine learning to extract genome-wide transcriptional and epigenomic signals for use in drug development and clinical decision-making.
Leadership & Board
- Current Number of Employees
- 71
- Current LinkedIn Followers
- 6,941
Latest Estimated Valuation
- Estimated Valuation
- ―
- Total Amount Raised
- $84M
- Total Funding Rounds
- 1
- Latest Funding Amount
- $84M
- Latest Funding Round
- Series B
- Post-Money Valuation
- ―
Employee Trend
Precede Biosciences had 71 employees as of October 12, 2026. The number of employees increased by 3 (4.41%) week-over-week.
Social Trend
Precede Biosciences had 6,941 followers as of October 12, 2026. The number of followers increased by 57 (0.83%) week-over-week.
Funding Round
| Funding Date | Funding Round | Amount Raised | Post-Money Valuation |
|---|---|---|---|
| Jan 12, 2026 | Series B | $83.50M | ― |
Investors
| Investor Name | Funding Round |
|---|---|
| Bristol-Myers Squibb | Series B |
| UPMC Enterprises | Series B |
| Alexandria Venture Investments | Series B |
| Lilly Asia Ventures | Series B |
| 5AM Ventures | Series B |
| Mirae Asset Capital | Series B |
| Illumina Ventures | Series B |
| Labcorp Venture Fund | Series B |
Similar Companies
A snapshot of private companies similar to Precede Biosciences, helping you discover and navigate related company profiles.
Related News and Analysis
